Actively Recruiting
Pharmacogenetics of Response to GLP1R Agonists
Led by University of Maryland, Baltimore · Updated on 2025-07-01
600
Participants Needed
1
Research Sites
298 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before and after administration of drug). 2. Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs (before and after administration of drug). Genotyping will be conducted using a high-density array with comprehensive coverage of DNA sequence variants. In addition, the analysis will leverage a global imputation panel generated from 1,025 Amish individuals.
CONDITIONS
Official Title
Pharmacogenetics of Response to GLP1R Agonists
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI greater than or equal to 27 kg/m2
- Of Amish descent
You will not qualify if you...
- Woman of childbearing age who is sexually active
- History of diabetes (HbA1c > 6.5% or random glucose >200 mg/dL)
- Known allergy to semaglutide
- Medical issues increasing risk as judged by research physician or PIs
- eGFR less than 60 mL/min/1.73 sq. m.
- Hematocrit less than 35%
- TSH less than 0.4 or greater than 5.5
- AST or ALT greater than 2 times the upper limit of normal
- Unable to discontinue drugs, vitamins, or supplements that might alter semaglutide response
- Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Amish Research Clinic
Lancaster, Pennsylvania, United States, 17602
Actively Recruiting
Research Team
A
Amber L Beitelshees, PharmD
CONTACT
S
Simeon I Taylor, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here